42556-1 |
Event description.equipment &or device |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Event description equipment/device MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42556-1 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Event Desc equipment/device MERSTH |
|
|
|
N |
|
Event Desc equipment/device; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42557-9 |
Event description.laboratory |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Event description laboratory MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42557-9 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Event Desc lab MERSTH |
|
|
|
N |
|
Event Desc lab; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42558-7 |
Event description.transfusion service |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Event description transfusion service MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42558-7 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Event Desc transfusion service MERSTH |
|
|
|
N |
|
Event Desc transfusion service; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random; Tx |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42559-5 |
Event description.administrative |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Event description administrative MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42559-5 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Event Desc admin MERSTH |
|
|
|
N |
|
Event Desc admin; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
4256-4 |
Flecainide |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Flecainide [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4256-4 |
|
|
|
|
Observation |
|
|
|
0 |
Flecainide Dose |
|
|
|
Y |
|
Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random; Tambocor |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
42560-3 |
Event description.complaint |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Event description complaint MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42560-3 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Event Desc complaint MERSTH |
|
|
|
N |
|
Event Desc complaint; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42561-1 |
Event description.environmental hazard &or safety |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Event description environmental hazard/safety MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42561-1 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Event Desc envir hazard/safety MERSTH |
|
|
|
N |
|
Event Desc envir hazard/safety; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42562-9 |
Event description.crime &or intentional harm/Patient disappearance |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Event description crime/intentional harm/Patient disappearance MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42562-9 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Evnt Dsc crime/intnt hrm/Pt disp MERSTH |
|
|
|
N |
|
Evnt Dsc crime/intnt hrm; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Pt disp; Random |
2.5 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42563-7 |
Event description.adverse event |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Event description adverse event MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42563-7 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Event Desc AE MERSTH |
|
|
|
N |
|
AE; Event Desc AE; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42564-5 |
Contributing factor.technical |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Contributing Factor technical MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42564-5 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Contrib Fact technical MERSTH |
|
|
|
N |
|
Contrib Fact technical; Fac; Fact; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42565-2 |
Contributing factor.organization |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Contributing Factor organization MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42565-2 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Contrib Fact organization MERSTH |
|
|
|
N |
|
Contrib Fact organization; Fac; Fact; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42566-0 |
Contributing factor.communication &or documentation |
Find |
^Patient |
Pt |
Nom |
Observed.MERSTH |
|
ACTIVE |
Contributing Factor communication/Documentation MERSTH |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATIENT SAFETY |
|
42566-0 |
|
Observed.MERSTH |
|
|
|
|
|
|
0 |
Contrib Fact communication/doc MERSTH |
|
|
|
N |
|
Contrib Fact communication/doc; Fac; Fact; Finding; Findings; Medical Event Reporting System-Total Health System; Nominal; Patient safety; Point in time; Random |
2.27 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42567-8 |
Calcium.ionized |
MSCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Calcium.ionized [Mass or Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
42567-8 |
|
|
|
|
Both |
|
|
|
0 |
Ca-I SerPl-msCnc |
|
|
|
N |
|
Ca; Ca-I; Cal; Calcium active; Calcium free; Chemistry; Coagulation factor I; ICA; Ion; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.42 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42568-6 |
Fibrinogen |
MSCnc |
PPP |
Pt |
Qn |
Coag |
|
DISCOURAGED |
Fibrinogen [Mass or Moles/volume] in Platelet poor plasma by Coagulation assay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
42568-6 |
|
Coag |
|
|
Both |
|
|
|
0 |
Fibrinogen PPP-msCnc |
|
|
|
N |
|
Clot; Clottable; COAGULATION; Coagulation assay; Coagulation factor I; FGN; Hematology; Heme; Level; Plas; Platelet poor plasma; Point in time; QNT; Quan; Quant; Quantitative; Random; Tilt tube |
2.42 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42569-4 |
Potassium |
MSCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Potassium [Mass or Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
42569-4 |
|
|
|
|
Both |
|
|
|
0 |
Potassium SerPl-msCnc |
|
|
|
N |
|
Chemistry; k; K+; Level; Pl; Plasma; Plsm; Point in time; Potass; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.42 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
4257-2 |
5-Fluorocytosine |
Mass |
Dose |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated 5-Fluorocytosine [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4257-2 |
|
|
|
|
|
|
|
|
0 |
Deprecated 5-fluorocytosine Dose |
|
|
|
|
|
Alcobon; Ancobon; Ancotil; Dose med or substance; DRUG DOSES; Flucytosine; Fluorocytosin; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42570-2 |
Sodium |
MSCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Sodium [Mass or Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
42570-2 |
|
|
|
|
Both |
|
|
|
0 |
Sodium SerPl-msCnc |
|
|
|
N |
|
Chemistry; Level; Na; Na+; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.42 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42571-0 |
Urea |
MSCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Urea [Mass or Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
42571-0 |
|
|
|
|
Both |
|
|
|
0 |
Urea SerPl-msCnc |
|
|
|
N |
|
Chemistry; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.42 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
42572-8 |
11-Deoxycortisol |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycortisol [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
42572-8 |
|
|
|
|
Both |
|
|
|
0 |
11DC Ur-mCnc |
|
|
|
N |
|
11DC; Chemistry; Compound S; Cortexolone; Cortodoxone; Deoxycortisol; Desoxycortisol; Level; Mass concentration; Metopirone; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
42573-6 |
18-Hydroxycorticosterone |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
18-Hydroxycorticosterone [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
42573-6 |
|
|
|
|
Both |
|
|
|
0 |
18OHB Ur-mCnc |
|
|
|
N |
|
18OHB; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
42574-4 |
1-Naphthol |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
1-Naphthol [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42574-4 |
|
|
|
|
Both |
|
|
|
0 |
1Naphthol Ur Ql |
|
|
|
N |
|
1Naphthol; alpha-naphthol; Carbaryl metabolite; DRUG/TOXICOLOGY; Drugs; i; Naphthalene metabolite; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42575-1 |
Amoxicillin Ab.IgE/IgE.total |
AFr |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Amoxicillin IgE Ab/IgE total in Serum |
|
MIN |
DefinitionDescription |
|
|
% response |
|
|
|
|
|
|
ALLERGY |
|
42575-1 |
|
|
|
|
Both |
|
|
|
0 |
Amoxicillin IgE/IgE total % |
|
|
|
N |
|
%; ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Amox; Amoxicilloyl; Amoxil; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Bristamox; c204; c6; IgE total; Immune globulin E; Immunoglobulin E; Larotid; Moxalin; Point in time; Polymox; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Sumox; Tot; Total IgE; Totl; Trimox; Wymox |
2.7 |
2.16 |
|
|
|
|
|
|
|
%{response} |
|
|
The divisor /IgE.total has been added to this term to clarify that the denominator is the patient's total IgE, and Property has been corrected from Ratio to AFr. |
0 |
42576-9 |
Amphetamine |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Amphetamine [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
42576-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Amphet Bld Cfm-mCnc |
|
|
|
N |
|
Addiction; Amph; Amphet; Amphetam; Amphetamines; Ampht; Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Speed; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
42577-7 |
Ampicillin Ab.IgE/IgE.total |
AFr |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Ampicillin IgE Ab/IgE total in Serum |
|
MIN |
DefinitionDescription |
|
|
% response |
|
|
|
|
|
|
ALLERGY |
|
42577-7 |
|
|
|
|
Both |
|
|
|
0 |
Ampicillin IgE/IgE total % |
|
|
|
N |
|
%; ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Amcil; Amicil; Amp; Ampicilloyl; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; c203; c5; IgE total; Immune globulin E; Immunoglobulin E; Omnipen; Penbritin; Point in time; Polycillin; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Tot; Total IgE; Totl |
2.7 |
2.16 |
|
|
|
|
|
|
|
%{response} |
|
|
The divisor /IgE.total has been added to this term to clarify that the denominator is the patient's total IgE, and Property has been corrected from Ratio to AFr. |
0 |
42578-5 |
Artifact |
PrThr |
Urine sed |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Artifact [Presence] in Urine sediment by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
UA |
|
42578-5 |
|
Microscopy.light |
|
|
Observation |
|
|
|
0 |
Artifact UrnS Ql Micro |
|
|
|
N |
|
Kidney; LM; Micro; Micros; Microscopic; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |